Catumaxomab: Difference between revisions

	WikiDoc Resources for Catumaxomab
Articles
Most recent articles on Catumaxomab Most cited articles on Catumaxomab Review articles on Catumaxomab Articles on Catumaxomab in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Catumaxomab Images of Catumaxomab Photos of Catumaxomab Podcasts & MP3s on Catumaxomab Videos on Catumaxomab
Evidence Based Medicine
Cochrane Collaboration on Catumaxomab Bandolier on Catumaxomab TRIP on Catumaxomab
Clinical Trials
Ongoing Trials on Catumaxomab at Clinical Trials.gov Trial results on Catumaxomab Clinical Trials on Catumaxomab at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Catumaxomab NICE Guidance on Catumaxomab NHS PRODIGY Guidance FDA on Catumaxomab CDC on Catumaxomab
Books
Books on Catumaxomab
News
Catumaxomab in the news Be alerted to news on Catumaxomab News trends on Catumaxomab
Commentary
Blogs on Catumaxomab
Definitions
Definitions of Catumaxomab
Patient Resources / Community
Patient resources on Catumaxomab Discussion groups on Catumaxomab Patient Handouts on Catumaxomab Directions to Hospitals Treating Catumaxomab Risk calculators and risk factors for Catumaxomab
Healthcare Provider Resources
Symptoms of Catumaxomab Causes & Risk Factors for Catumaxomab Diagnostic studies for Catumaxomab Treatment of Catumaxomab
Continuing Medical Education (CME)
CME Programs on Catumaxomab
International
Catumaxomab en Espanol Catumaxomab en Francais
Business
Catumaxomab in the Marketplace Patents on Catumaxomab
Experimental / Informatics
List of terms related to Catumaxomab

Catumaxomab
Monoclonal antibody
Type	Trifunctional antibody
Source	Template:Infobox drug/mab source
Target	EpCAM, CD3
Clinical data
Trade names	Removab
AHFS/Drugs.com	International Drug Names
[[Regulation of therapeutic goods \|Template:Engvar data]]	EU EMA: by INN;
Routes of; administration	intraperitoneal infusion
ATC code	L01XC09 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
CAS Number	509077-98-9 ;
ChemSpider	NA ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
(what is this?) (verify)

VisualWikitext

Latest revision as of 15:36, 9 April 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Catumaxomab^[1] (trade name Removab) is a rat-mouse hybrid monoclonal antibody which is used to treat malignant ascites, a condition occurring in patients with metastasizing cancer. It binds to antigens CD3 and EpCAM. It is in clinical trials in the United States currently and is used in Europe. It was developed by Fresenius Biotech and Trion Pharma (Germany).

History

Catumaxomab was developed by Trion Pharma, based on preliminary work by the Helmholtz Zentrum München. Fresenius Biotech conducted clinical trials and filed the drug for approval with the European Medicines Agency (EMA). It was approved in Europe on 20 April 2009.

Indications

The drug is approved for the treatment of malignant ascites in patients with EpCAM-positive cancer if a standard therapy is not available. Ascites is an accumulation of fluid in the peritoneal cavity.

Application

The usual treatment of malignant ascites is to puncture the peritoneum to let the accumulated fluid drain out. After the puncture, catumaxomab is given as an intraperitoneal infusion. The procedure is repeated four times within about eleven days. It has been shown that puncture free survival can be increased from 11 to 46 days with this treatment.

Adverse effects

Common adverse effects include fever, nausea and vomiting. Fever and pain should be controlled by giving NSAIDs, analgetics or antipyretics before application of catumaxomab.

Chemical structure

Catumaxomab consists of one "half" (one heavy chain and one light chain) of an anti-EpCAM antibody and one half of an anti-CD3 antibody, so that each molecule of catumaxomab can bind both EpCAM and CD3. In addition, the Fc-region can bind to an Fc receptor on accessory cells like other antibodies, which has led to calling the drug a trifunctional antibody.

Mechanism of action

Many types of cancer cells carry EpCAM (epithelial cell adhesion molecule) on their surface. By binding to such a cell via one arm, to a T lymphocyte via the other arm and to an antigen-presenting cell like a macrophage, a natural killer cell or a dendritic cell via the heavy chains, an immunological reaction against the cancer cell is triggered. Removing cancer cells from the abdominal cavity reduces the tumour burden which is seen as the cause for ascites in cancer patients.

References

↑ Linke, Rolf (2010). "Catumaxomab: Clinical development and future directions". mAbs. 2 (2): 129–136. doi:10.4161/mabs.2.2.11221. Unknown parameter |coauthors= ignored (help)

[1] Linke, Rolf (2010). "Catumaxomab: Clinical development and future directions". mAbs. 2 (2): 129–136. doi:10.4161/mabs.2.2.11221. Unknown parameter |coauthors= ignored (help)

[1]

@@ Line 1: / Line 1: @@
-{{drugbox-mab
+{{Drugbox
-| image =
+| Verifiedfields = changed
-| source = [[Rat]]-[[murine]] hybrid
+| verifiedrevid = 460022109
-| target = EpCAM [[CD3]]
+<!--Monoclonal antibody data-->
+| type = mab
+| mab_type = 3funct
+| source = axo
+| target = [[EpCAM]], [[CD3 (immunology)|CD3]]
+<!--Clinical data-->
+| tradename = Removab
+| Drugs.com = {{drugs.com|international|catumaxomab}}
+| licence_EU = Removab
+| pregnancy_AU =
+| pregnancy_US =
+| pregnancy_category =
+| legal_AU =
+| legal_CA =
+| legal_UK =
+| legal_US =
+| legal_status = Rx-only
+| routes_of_administration = [[Intraperitoneal injection|intraperitoneal]] infusion
+<!--Pharmacokinetic data-->
+| bioavailability =
+| protein_bound =
+| metabolism =
+| elimination_half-life =
+| excretion =
+<!--Identifiers-->
+| CAS_number_Ref = {{cascite|changed|??}}
 | CAS_number = 509077-98-9
-| ATC_prefix =
+| ATC_prefix = L01
-| ATC_suffix =
+| ATC_suffix = XC09
 | PubChem =
-| DrugBank =
+| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
-| chemical_formula =
+| DrugBank =
-| molecular_weight =
+| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
-| bioavailability =
+| ChemSpiderID = NA
-| protein_bound =
-| metabolism =
+<!--Chemical data-->
-| elimination_half-life =
+| chemical_formula =
-| excretion =
+| molecular_weight =
-| pregnancy_AU =
-| pregnancy_US =
-| pregnancy_category =
-| legal_AU =
-| legal_CA =
-| legal_UK =
-| legal_US =
-| legal_status =
-| routes_of_administration =
 }}
+__NOTOC__
 {{SI}}
-{{EH}}
+{{CMG}}
+==Overview==
+'''Catumaxomab'''<ref>{{cite journal|last=Linke|first=Rolf|coauthors=Anke Klein and Diane Seimetz|title=Catumaxomab: Clinical development and future directions|journal=mAbs|year=2010|volume=2|issue=2|pages=129–136|doi=10.4161/mabs.2.2.11221|url=http://www.landesbioscience.com/journals/17/article/11221/}}</ref> (trade name '''Removab''') is a [[rat]]-[[mouse]] hybrid [[monoclonal antibody]] which is used to treat [[malignant]] [[ascites]], a condition occurring in patients with [[Metastasis|metastasizing]] cancer. It binds to antigens [[CD3 (immunology)|CD3]] and [[EpCAM]]. It is in clinical trials in the [[United States]] currently and is used in [[Europe]]. It was developed by [[Fresenius SE|Fresenius]] Biotech and [[Trion Pharma]] ([[Germany]]).
-==Overview==
+==History==
-'''Catumaxomab''' (removab®) is a [[rat]]-murine hybrid [[monoclonal antibody]] and which it's used to treat some cancers such as platinum-refractory ovarian cancer, malignant ascites, and gastric cancer. It binds to antigen [[CD3]] and is also trifunctional.  It is in clinical trials in the United States currently and is used in Europe.
+Catumaxomab was developed by Trion Pharma, based on preliminary work by the [[Helmholtz Zentrum München]]. Fresenius Biotech conducted [[clinical trial]]s and filed the drug for approval with the [[European Medicines Agency]] (EMA). It was approved in Europe on 20 April 2009.
+==Indications==
+The drug is approved for the treatment of malignant ascites in patients with EpCAM-positive cancer if a standard therapy is not available. Ascites is an accumulation of fluid in the [[peritoneal cavity]].
+===Application===
+The usual treatment of malignant ascites is to puncture the [[peritoneum]] to let the accumulated fluid drain out. After the puncture, catumaxomab is given as an [[intraperitoneal]] infusion. The procedure is repeated four times within about eleven days. It has been shown that puncture free survival can be increased from 11 to 46 days with this treatment.
+==Adverse effects==
+Common adverse effects include fever, [[nausea]] and vomiting. Fever and pain should be controlled by giving [[NSAID]]s, [[analgetic]]s or [[antipyretics]] before application of catumaxomab.
+==Chemical structure==
+Catumaxomab consists of one "half" (one [[Immunoglobulin heavy chain|heavy chain]] and one [[Immunoglobulin light chain|light chain]]) of an anti-EpCAM antibody and one half of an anti-CD3 antibody, so that each molecule of catumaxomab can bind both EpCAM and CD3. In addition, the Fc-region can bind to an [[Fc receptor]]  on accessory cells like other antibodies, which has led to calling the drug a [[trifunctional antibody]].
+[[File:Catumaxomab structure.png|none|left|400px]]
+==Mechanism of action==
+Many types of cancer cells carry EpCAM (epithelial cell adhesion molecule) on their surface. By binding to such a cell via one arm, to a [[T lymphocyte]] via the other arm and to an [[antigen-presenting cell]] like a [[macrophage]], a [[natural killer cell]] or a [[dendritic cell]] via the heavy chains, an immunological reaction against the cancer cell is triggered. Removing cancer cells from the abdominal cavity reduces the tumour burden which is seen as the cause for ascites in cancer patients.
-It basically works by linking your T-lymphocytes with the cancer cells.
+[[File:Catumaxomab mechanism.png|none|left|400px]]
+==References==
+{{reflist|2}}
-{{rat-murinehybridmonoclonals}}
+[[Category:Drug]]
-{{SIB}}
-[[Category:Monoclonal antibodies]]
-[[Category:Cancer treatments]]
-{{WikiDoc Help Menu}}
-{{WS}}